Combination therapy with an ACE inhibitor and an angiotensin receptor blocker
for diabetic nephropathy: a meta-analysis.
The VA NEPHRON-D (Veterans Affairs Nephropathy in Diabetes) study involved 1,448 patients with type 2 diabetes and moderate diabetic nephropathy who were treated for at least 30 days with 100 mg daily of the angiotensin receptor blocker
(ARB) losartan, as is standard practice in patients with diabetes.
The measures identified for heart failure include discharge instructions, left ventricular function assessment as measured by an echocardiogram, discharge prescription for an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker
for left ventricular systolic dysfunction, and smoking cessation advice/counseling.
Norvasc, a calcium channel blocker, relaxes blood vessels, while olmesartan uses an angiotensin receptor blocker
to ease blood-vessel constriction.
An angiotensin receptor blocker
(ARB) discovered by Takeda, TAK-491 helps lower blood pressure by suppressing the action of vasopressor hormone Angiotensin II.
Novartis AG, Basel, Switzerland, announced the US Food and Drug Administration (FDA) has approved Diovan, the most prescribed angiotensin receptor blocker
(ARB) worldwide, for a new indication to reduce cardiovascular death in patients with high risk (with left ventricular failure or left ventricular dysfunction) following a heart attack.
The drug is Entresto[TM], a combination of the neprilysin inhibitor sacubitril and valsartan, an angiotensin receptor blocker
Entresto is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other angiotensin receptor blocker
The company stated that Entresto is usually administered along with other heart failure therapies in place of an ACE inhibitor or other angiotensin receptor blocker
. The product is a first in class angiotensin receptor neprilysin inhibitor that decreases strain on a failing heart.
Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker
use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III.
All women who were discharged on an ACE inhibitor or angiotensin receptor blocker
, and lipid therapy, and 90% of those discharged on a [beta]-blocker, remained on their medications at 1-year follow-up.
Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker
added to angiotensin converting enzyme inhibitor therapy in patients with heart failure.